790 related articles for article (PubMed ID: 2501477)
1. Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain.
Tadano T; Satoh S; Satoh N; Kisara K; Arai Y; Kim SK; Kinemuchi H
J Pharmacol Exp Ther; 1989 Jul; 250(1):254-60. PubMed ID: 2501477
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of brain MAO-A and animal behaviour induced by p-hydroxyamphetamine.
Arai Y; Kim SK; Kinemuchi H; Tadano T; Oyama K; Satoh N; Kisara K
Brain Res Bull; 1991 Jul; 27(1):81-4. PubMed ID: 1933439
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of MAO-A activity enhances behavioural activity of rats assessed using water maze and open arena tasks.
Barbelivien A; Nyman L; Haapalinna A; Sirviö J
Pharmacol Toxicol; 2001 Jun; 88(6):304-12. PubMed ID: 11453370
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of brain type A monoamine oxidase and 5-hydroxytryptamine uptake by two amphetamine metabolites, p-hydroxyamphetamine and p-hydroxynorephedrine.
Arai Y; Kim SK; Kinemuchi H; Tadano T; Satoh SE; Satoh N; Kisara K
J Neurochem; 1990 Aug; 55(2):403-8. PubMed ID: 2370545
[TBL] [Abstract][Full Text] [Related]
5. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl].
Severina IS
Biokhimiia; 1979 Feb; 44(2):195-207. PubMed ID: 435561
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor.
Hewton R; Salem A; Irvine RJ
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):1051-7. PubMed ID: 17714093
[TBL] [Abstract][Full Text] [Related]
7. The effect of repeated administration of (-) deprenyl on the phenylethylamine-induced stereotypy in rats.
Timár J; Knoll B
Arch Int Pharmacodyn Ther; 1986 Jan; 279(1):50-60. PubMed ID: 3083795
[TBL] [Abstract][Full Text] [Related]
8. Type-specific localization of monoamine oxidase in the enteric nervous system: relationship to 5-hydroxytryptamine, neuropeptides, and sympathetic nerves.
Gershon MD; Sherman DL; Pintar JE
J Comp Neurol; 1990 Nov; 301(2):191-213. PubMed ID: 2124589
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
Löscher W; Lehmann H; Teschendorf HJ; Traut M; Gross G
J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835
[TBL] [Abstract][Full Text] [Related]
10. Monoamine oxidase and head-twitch response in mice. Mechanisms of alpha-methylated substrate derivatives.
Nakagawasai O; Arai Y; Satoh SE; Satoh N; Neda M; Hozumi M; Oka R; Hiraga H; Tadano T
Neurotoxicology; 2004 Jan; 25(1-2):223-32. PubMed ID: 14697897
[TBL] [Abstract][Full Text] [Related]
11. Short-term erythrosine B-induced inhibition of the brain regional serotonergic activity suppresses motor activity (exploratory behavior) of young adult mammals.
Dalal A; Poddar MK
Pharmacol Biochem Behav; 2009 Jun; 92(4):574-82. PubMed ID: 19264092
[TBL] [Abstract][Full Text] [Related]
12. Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives.
Inoue H; Castagnoli K; Van Der Schyf C; Mabic S; Igarashi K; Castagnoli N
J Pharmacol Exp Ther; 1999 Nov; 291(2):856-64. PubMed ID: 10525109
[TBL] [Abstract][Full Text] [Related]
13. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
Miklya I
Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
[TBL] [Abstract][Full Text] [Related]
14. Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system.
Blier P; De Montigny C; Azzaro AJ
J Pharmacol Exp Ther; 1986 Jun; 237(3):987-94. PubMed ID: 2423685
[TBL] [Abstract][Full Text] [Related]
15. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
Lamensdorf I; Youdim MB; Finberg JP
J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
[TBL] [Abstract][Full Text] [Related]
16. High-throughput screening for monoamine oxidase-A and monoamine oxidase-B inhibitors using one-step fluorescence assay.
Guang HM; Du GH
Acta Pharmacol Sin; 2006 Jun; 27(6):760-6. PubMed ID: 16723097
[TBL] [Abstract][Full Text] [Related]
17. The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons.
Demarest KT; Smith DJ; Azzaro AJ
J Pharmacol Exp Ther; 1980 Nov; 215(2):461-8. PubMed ID: 7441510
[TBL] [Abstract][Full Text] [Related]
18. Thyroid iodide transport is reduced by administration of monoamine oxidase A inhibitors to rats.
Cabanillas AM; Masini-Repiso AM; Costamagna ME; Pellizas C; Coleoni AH
J Endocrinol; 1994 Nov; 143(2):303-8. PubMed ID: 7829993
[TBL] [Abstract][Full Text] [Related]
19. Monoamine oxidase in pancreatic islets, exocrine pancreas, and liver from rats. Characterization with clorgyline, deprenyl, pargyline, tranylcypromine, and amezinium.
Lenzen S; Nahrstedt H; Panten U
Naunyn Schmiedebergs Arch Pharmacol; 1983 Nov; 324(3):190-5. PubMed ID: 6419132
[TBL] [Abstract][Full Text] [Related]
20. Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain.
Olmos G; Gabilondo AM; Miralles A; Escriba PV; García-Sevilla JA
Br J Pharmacol; 1993 Mar; 108(3):597-603. PubMed ID: 8385528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
